Stock Insider Trading (from SEC Form 4)
XENT / Intersect ENT, Inc. insiders include Kaufman Richard E (Sr VP& Chief Operating Officer), Tansey Casey M (), Wolbeck Amy (V.P. Regulatory Affairs & Qlty), Earnhardt Lisa D (President and CEO), Matteucci Paul A, MOLL FREDERIC H (), KPCB XI Associates, LLC, and KLEINER PERKINS CAUFIELD & BYERS XI-A LP VERNON W ANTHONY (), Lucchese Cynthia L (), HILLEMAN JERYL L (Chief Financial Officer), ROOT JONATHAN D, LIDDLE DAVID E, KRAUSZ STEVEN M, FEDERMAN IRWIN, Stambaugh James (VP Clinical Affairs), de Clercq Casper L., U S Venture Partners IX L P, Mead Dana G Jr. (), Parker Drake R. (Chief Business Officer), CARSCADDEN GWEN R. (Chief People Officer), KLEINER PERKINS CAUFIELD & BYERS XI B LP, Lehman David Aaron (General Counsel), GALLAHUE KIERAN (), YOUNG PHILIP M, Presidio Management Group IX, L.L.C., .
Intersect ENT, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.
Stop missing out on important events!
|Tran Value||Post Value||Percent
Earnhardt Lisa D
HILLEMAN JERYL L
Kaufman Richard E
Lehman David Aaron
CARSCADDEN GWEN R.
Parker Drake R.
MOLL FREDERIC H
Mead Dana G Jr.
VERNON W ANTHONY
Tansey Casey M
Lucchese Cynthia L
de Clercq Casper L.
KLEINER PERKINS CAUFIELD & BYERS XI-A LP
KLEINER PERKINS CAUFIELD & BYERS XI B LP
KPCB XI Associates, LLC
Presidio Management Group IX, L.L.C.
U S Venture Partners IX L P
KRAUSZ STEVEN M
LIDDLE DAVID E
Matteucci Paul A
ROOT JONATHAN D
YOUNG PHILIP M
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
Related News Stories
Intersect ENT, Inc. (XENT - Free Report) received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients. (66-0)
* James Flynn reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (bit.ly/2jwmJXW) Further company coverage:
* Intersect ENT Inc - FDA has set a pdufa target action date of January 7, 2018
Good afternoon, and welcome to the Intersect ENT Third Quarter 2017 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded.
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (389-2)
Chicago, IL – October 11, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IDEXX Laboratories, Inc. (Nasdaq:(IDXX - Free Report) – Free Report), Steris Corp. (NYSE:(STE - Free Report) – Free Report), K2M Group Holdings, Inc. (195-0)
While the Wall Street is gearing up for the third-quarter releases, the Republicans have lost another battle pertaining to the repeal of Affordable Care Act (ACA), or Obamacare, with the recent Graham-Cassidy bill defeat. (76-0)
Trump’s failure to pass the Graham-Cassidy bill, which was targeting the termination of the Obamacare Act and seeking to replace it with a block grant of health care expenses for states every year, had stolen the limelight of late. (38-0)